Male infertility during antihypertensive therapy: are we addressing correctly the problem?

Authors

  • Antonio Simone Laganà Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University of Messina, Messina, Italy.
  • Francesco Padula Department of Prenatal Diagnosis, Altamedica Fetal Maternal Medical Centre, Rome, Italy.
  • Paola Iaconianni Department of Reproductive Medicine, Altamedica Fetal Maternal Medical Centre, Rome, Italy.
  • Simona Gatti Department of Reproductive Medicine, Altamedica Fetal Maternal Medical Centre, Rome, Italy.
Abstract:

Male fertility significantly decreased in the last 50 years, as showed in several studies reporting a reduction of sperm counts per ml in the seminal fluid. Several “acute” pharmacological treatments, as antibiotics, could cause subclinical and temporary reduction of male fertility; conversely, long-term medical treatment may severely affect male fertility, although this effect could be considered transient in most of the cases. Thus, nowadays, several long-term pharmacological treatments may represent a clinical challenge. The association between several kind of antihypertensive drugs and reduction of male fertility has been showed in the mouse model, although the modification(s) which may alter this fine-regulated machinery are still far to be elucidated. Furthermore, well-designed observational studies and randomized controlled trials are needed to accurately define this association in human model, meaning a narrative overview synthesizing the findings of literature retrieved from searches of computerized databases. We strongly solicit future human studies (both observational and randomized clinical trials) on large cohorts with adequate statistical power which may clarify this possible association and the effects (reversible or permanent) of each drug. Furthermore, we suggest a close collaboration between general practitioners, cardiologists, and andrologists in order to choose the most appropriate antihypertensive therapy considering also patient’s reproductive desire and possible risk for his fertility.

similar resources

male infertility during antihypertensive therapy: are we addressing correctly the problem?

male fertility significantly decreased in the last 50 years, as showed in several studies reporting a reduction of sperm counts per ml in the seminal fluid. several “acute” pharmacological treatments, as antibiotics, could cause subclinical and temporary reduction of male fertility; conversely, long-term medical treatment may severely affect male fertility, although this effect could be conside...

full text

Male Infertility during Antihypertensive Therapy: Are We Addressing Correctly The Problem? (Review)

Male fertility significantly decreased in the last 50 years, as showed in several studies reporting a reduction of sperm counts per ml in the seminal fluid. Several “acute” pharmacological treatments, as antibiotics, could cause subclinical and temporary reduction of male fertility; conversely, long-term medical treatment may severely affect male fertility, although this effect could be conside...

full text

Male Infertility during Antihypertensive Therapy: Are We Addressing Correctly The Problem?

Male fertility significantly decreased in the last 50 years, as showed in several studies reporting a reduction of sperm counts per ml in the seminal fluid. Several "acute" pharmacological treatments, as antibiotics, could cause subclinical and temporary reduction of male fertility; conversely, long-term medical treatment may severely affect male fertility, although this effect could be conside...

full text

Are we studying and treating schizophrenia correctly?

New findings are rapidly revealing an increasingly detailed image of neural- and molecular-level dysfunction in schizophrenia, distributed throughout interconnected cortico-striato-pallido-thalamic circuitry. Some disturbances appear to reflect failures of early brain maturation, that become codified into dysfunctional circuit properties, resulting in a substantial loss of, or failure to develo...

full text

Are we correctly defining intermediate-risk pulmonary embolism?

We read with interest the article in CHEST (October 2014) by Doyen et al 1 regarding patent foramen ovale in pulmonary embolism (PE). Th e rationale for this article is the possible inclusion of transesophageal echocardiography into algorithms for the use of fi brinolytics in patients with intermediate-risk PE. Th e authors based their defi nition of intermediate-risk PE on the 2008 European So...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 10  issue 3

pages  267- 269

publication date 2016-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023